Sana Biotechnology to Present at September 2022 Investor Conferences
September 09 2022 - 4:05PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced that it will webcast its presentations at two
investor conferences in September. The presentations will feature a
business overview and update by Steve Harr, Sana’s President and
Chief Executive Officer.
- Sana will present at the Morgan Stanley 20th Annual Global
Healthcare Conference at 2:55 p.m. ET on Tuesday, September 13,
2022.
- Sana will present at the Jefferies Cell and Genetic Medicine
Summit at 2:00 p.m. ET on Thursday, September 29, 2022.
The webcasts will be accessible on the Investor Relations page
of Sana’s website at https://sana.com/. A replay of each
presentation will be available at the same location for 30 days
following the corresponding conference.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are a passionate
group of people working together to create an enduring company that
changes how the world treats disease. Sana has operations in
Seattle, Cambridge, South San Francisco, and Rochester. For more
information about Sana Biotechnology, please visit
https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision; the Company’s
participation in the Morgan Stanley 20th Annual Global Healthcare
Conference and the Jefferies Cell and Genetic Medicine Summit; and
the subject matter of the Company’s presentations at those
conferences. All statements other than statements of historical
facts contained in this press release, including, among others,
statements regarding the Company’s strategy, expectations, cash
runway and future financial condition, future operations, and
prospects, are forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. The Company has based these forward-looking statements
largely on its current expectations, estimates, forecasts and
projections about future events and financial trends that it
believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. These statements are subject to risks and uncertainties
that could cause the actual results to vary materially, including,
among others, the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of the Company’s current and future research and development
programs, preclinical and clinical trials, as well as the economic,
market and social disruptions due to the ongoing COVID-19 public
health crisis. For a detailed discussion of the risk factors that
could affect the Company’s actual results, please refer to the risk
factors identified in the Company’s SEC reports, including but not
limited to its Quarterly Report on Form 10-Q dated August 4, 2022.
Except as required by law, the Company undertakes no obligation to
update publicly any forward-looking statements for any reason.
Investor Relations & Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jul 2023 to Jul 2024